Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005438 | 0.95 | REN (0.70) | REN | |
| SCHEMBL19809098 | 0.95 | REN (0.70) | REN | |
| SCHEMBL17013112 | 0.94 | REN (0.75) | REN | |
| SCHEMBL17012900 | 0.93 | REN (0.67) | REN | |
| SCHEMBL17013660 | 0.91 | REN (0.81) | REN | |
| SCHEMBL17013647 | 0.91 | REN (0.81) | REN | |
| SCHEMBL17013658 | 0.91 | REN (0.81) | REN | |
| SCHEMBL17013663 | 0.90 | REN (0.79) | REN | |
| SCHEMBL17005474 | 0.89 | REN (0.67) | REN | |
| SCHEMBL19809100 | 0.89 | REN (0.67) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.